Redx Pharma (REDX): Entering the clinical stage
The new Board & Management team of Redx is focusing its financial resources (ca.£12.5m) on progressing its lead candidates in oncology and fibrotic disease into the clinic. The company has announced recently that the first patient has been treated with RXC004, a porcupine inhibitor indicated for a number of tumour types, in a Phase I/IIa proof-of-concept clinical trial. By entering humans, Redx has hit an important development milestone and evolved into a clinical-stage biopharmaceutical company. The group’s strategy was validated in 2017 by the successful disposal of its pre-clinical programme BTK for $40m.Redx Pharma is engaged in drug discovery, pre-clinical development and licensing. The principal activities of the business are the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. Co. is developing a porcupine inhibitor drug candidate, RXC004, as a cancer treatment using in vivo models of pancreatic and gastric cancer. ROCK1/2 inhibitors (known as systemic pan-Rock inhibitors) are known to induce hypotension. Co.'s ROCK inhibitor is designed to only work at the site of action in the gastrointestinal tract and degrades quickly, once absorbed, through enzyme-mediated metabolism in the blood, deeming it a soft inhibitor.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.